

SYNTHESIS OF AMINO-ACID DERIVATIVES OF CHRYSIN

M. V. Veselovskaya,^{1*} M. M. Garazd,¹ A. S. Ogorodniichuk,¹
Ya. L. Garazd,² and V. P. Khilya²

UDC 547.814.5

Various conjugates of amino acids with chrysin in which the amino acid was bonded through the C- or N-terminus to the flavone were prepared using peptide chemistry methods (symmetric anhydrides and activated esters).

Key words: flavonoids, flavones, chrysin, amino-acid derivatives.

Flavonoids are the most widely distributed compounds of natural origin. They can be found in practically all plant species. At present, flavonoids comprise about 6500 natural compounds [1]. The study of flavonoids is becoming increasingly interesting because of the important role that they play in the metabolism of plants and animals and their high and diversified biological activity [2]. Chrysin (5,7-dihydroxyflavone) is one of the most common flavonoids, has been isolated from various plant families [3, 4], and possesses, like its derivatives, a broad spectrum of biological activity. Thus, chrysin exhibits anticancer [5, 6], antioxidant [7, 8], anti-inflammatory [9, 10], vasodilating [11, 12], immunomodulating [13, 14], antibacterial [15, 16], antifungal [16], antiprotozoal [17], neuroprotective [18], hypotensive [19], and anti-allergy [20] activity. Chrysin derivatives possess hypoglycemic [21], anticancer [22-25], anti-inflammatory [26, 27], and antibacterial [15] action.

Considering the importance to the metabolism of all animals of amino acids and their derivatives, our goal was to synthesize chrysin derivatives with pharmacophores containing amino acids.


The amino-acid derivatives of chrysin were synthesized via two modification pathways. The first was based on formation of the ester of *N*-protected amino acid and phenolic compounds. The most suitable and convenient method for synthesizing 7-*O*-amino-acid chromone derivatives is the reaction of 7-hydroxychromones and symmetric anhydrides of *N*-substituted amino acids because the reaction proceeds under mild conditions and is not complicated by side reactions [28]. It has been used successfully to synthesize similar types of compounds [29, 30].

The hydroxyls of 5,7-dihydroxychromones have different reactivities because of the different influence of electron-donors, steric factors, and intramolecular H-bonds. Therefore, the 7-hydroxyl of the chromone system is acylated exclusively under mild conditions [31, 32].

Symmetric anhydrides of *N*-protected amino acids were prepared by reaction of dicyclohexylcarbodiimide (DCC) with two equivalents of the corresponding *N*-protected amino acid in anhydrous dioxane at 0°C. The amines of the amino acids were blocked with *t*-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and *p*-toluenesulfonic acid (Tos). Chrysin was acylated by the resulting amino-acid anhydrides at 0°C in anhydrous dioxane in the presence of catalytic amounts of 4-dimethylaminopyridine (DMAP) to produce *N*-protected 7-*O*-aminoacyl-5-hydroxy-2-phenylchromen-4-ones **2-20**. The products contained glycine (**2, 8**), L-alanine (**3, 9**), L-valine (**4, 10**), L-leucine (**5, 11**), L-isoleucine (**6, 12**), L-methionine (**13**), L-phenylalanine (**7, 14**), β -alanine (**15, 17, 19**), and 6-aminohexanoic acid (**16, 18, 20**).


The selective acylation of the chromone 7-hydroxyl was confirmed by PMR spectroscopy. The spectra of **2-20** contained resonances for the flavone ring, an amino-acid moiety, and the protecting group. The resonance of the 5-OH, which was involved in an intramolecular H-bond, appeared in the range 12.72-12.95 ppm. Derivatives **2-20** gave an intense brown color with alcoholic FeCl₃ due to formation of an intramolecular chelate complex.

1) Institute of Bioorganic and Petroleum Chemistry, National Academy of Sciences of Ukraine, 02094, Ukraine, Kiev, ul. Murmanskaya, 1, e-mail: gmm@i.com.ua; 2) Taras Shevchenko Kiev National University, 01033, Ukraine, Kiev, ul. Vladimirska, 64. Translated from *Khimiya Prirodnykh Soedinenii*, No. 6, pp. 569-574, November-December, 2008. Original article submitted January 14, 2008.



2, 8: R = H; **3, 9:** R = CH₃; **4, 10:** R = CH(CH₃)₂; **5, 11:** R = CH₂CH(CH₃)₂; **6, 12:** R = CH₂CH(CH₃)CH₂CH₃
7, 14: R = CH₂Ph; **13:** R = CH₂CH₂SCH₃; **15, 17, 19:** n = 2; **16, 18, 20:** n = 5

The second approach to modifying chrysin with amino acids was based on the method of activated esters, which is widely used in peptide chemistry. Selective alkylation of the chrysin 7-hydroxyl under Williamson reaction conditions by ethylbromoacetate produced ethyl ester **21**, saponification of which by NaOH in aqueous propanol-2 and subsequent acidolysis of the reaction mixture formed [(5-hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetic acid (**22**).



23: R = H; **24:** R = CH₃; **25:** R = CH(CH₃)₂; **26:** R = CH₂CH₂SCH₃; **27:** R = CH₂Ph; **28:** R = Ph; **30:** n = 2; **31:** n = 5

The carboxylic acid was activated using *N*-hydroxysuccinimide to form highly reactive esters without racemizing the reaction products [33]. This method was used successfully to synthesize similar types of compounds [30, 34]. The activated ester was prepared by reacting starting acid **22** and *N*-hydroxysuccinimide (SuOH) in anhydrous DMF with diisopropylcarbodiimide (DIC) as the condensing agent. Reaction of the activated ester and sodium salts of the amino acids in

DMF:H₂O at room temperature with subsequent acidolysis of the resulting salts gave in high yields **23-33** with a free carboxylic acid.

The synthesis gave chrysin derivatives modified with glycine (**23**), L-alanine (**24**), L-valine (**25**), L-methionine (**26**), L-phenylalanine (**27**), L- α -phenylglycine (**28**), and β -alanine (**29**) and 4-aminobutanoic (**30**), 6-aminohexanoic (**31**), and *trans*-4-aminomethylcyclohexanecarboxylic (**32**) acids in addition to glycyglycine (**33**). PMR spectra of **23-33** contained resonances for chrysin, the amino-acid moiety, the amide bond at 8.12-8.93 ppm, and the free carboxylic acid at 11.90-12.65 ppm.

EXPERIMENTAL

The course of reactions and purity of products were monitored by TLC on Merck 60 F254 plates with elution by CHCl₃:CH₃OH (9:1). Melting points were determined on a Kofler block. PMR spectra were recorded on Varian VXR-300 and Mercury 400 spectrometers at 300 and 400 MHz, respectively, vs. TMS (internal standard). Elemental analyses of all compounds agreed with those calculated.

5,7-Dihydroxyflavone was prepared as before [35].

N-Substituted 7-O-Aminoacyl-5-hydroxy-2-phenylchromen-4-ones 2-20. A cooled (0°C) solution of the appropriate *N*-substituted amino acid (9 mmol) in anhydrous dioxane (20 mL) was treated with DCC (0.93 g, 4.5 mmol) and stirred vigorously for 20-30 min at 0°C. The precipitate of dicyclohexylurea was filtered off. The resulting symmetric anhydride was treated with chrysin (1.02 g, 4 mmol) in anhydrous dioxane (20 mL) and DMAP (20 mg), held for 1-2 h at room temperature, and stirred vigorously (finish of the reaction was determined using TLC). Solvent was removed in vacuo. The solid was dissolved in ethylacetate (50 mL) and washed successively with NaHCO₃ solution (2 × 50 mL), water (50 mL), and saturated NaCl solution (50 mL). The organic phase was dried over anhydrous MgSO₄. Solvent was removed in vacuo. The solid was crystallized from propanol-2.

7-O-(*N*-*t*-Butyloxycarbonylglycyl)-5-hydroxy-2-phenylchromen-4-one (2), yield 69%, mp 218-219°C, C₂₂H₂₁NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ , ppm, J/Hz): 1.44 [9H, s, (CH₃)₃C], 4.14 (2H, d, J = 5.7, CH₂-2''), 6.54 (1H, br.m, CONH), 6.61 (1H, d, J = 2.1, H-6), 6.92 (1H, s, H-3), 7.01 (1H, d, J = 2.1, H-8), 7.56-7.68 (3H, m, H-3', H-4', H-5'), 8.11 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.91 (1H, s, OH-5).

7-O-(*N*-*t*-Butyloxycarbonyl-L-alanyl)-5-hydroxy-2-phenylchromen-4-one (3), yield 78%, mp 192-193°C, C₂₃H₂₃NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ , ppm, J/Hz): 1.45 [9H, s, (CH₃)₃C], 1.55 (3H, d, J = 7.5, CH₃-3''), 4.44 (1H, m, H-2''), 6.59 (1H, d, J = 7.2, CONH), 6.61 (1H, d, J = 2.1, H-6), 6.93 (1H, s, H-3), 7.01 (1H, d, J = 2.1, H-8), 7.56-7.68 (3H, m, H-3', H-4', H-5'), 8.12 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.90 (1H, s, OH-5).

7-O-(*N*-*t*-Butyloxycarbonyl-L-valyl)-5-hydroxy-2-phenylchromen-4-one (4), yield 73%, mp 188-189°C, C₂₅H₂₇NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ , ppm, J/Hz): 1.11 (6H, d, J = 6.6, CH₃-4'', CH₃-3''), 1.45 [9H, s, (CH₃)₃C], 2.34 (1H, m, H-3''), 4.29 (1H, t, J = 6.0, H-2''), 6.52 (1H, d, J = 7.5, CONH), 6.60 (1H, d, J = 2.1, H-6), 6.95 (1H, s, H-3), 7.02 (1H, d, J = 2.1, H-8), 7.60-7.70 (3H, m, H-3', H-4', H-5'), 8.13 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.94 (1H, s, OH-5).

7-O-(*N*-*t*-Butyloxycarbonyl-L-leucyl)-5-hydroxy-2-phenylchromen-4-one (5), yield 68%, mp 181-182°C, C₂₆H₂₉NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ , ppm, J/Hz): 1.03 (6H, d, J = 5.7, CH₃-5'', CH₃-4''), 1.45 [9H, s, (CH₃)₃C], 1.82-1.87 (3H, m, CH₂-3'', H-4''), 4.41 (1H, m, H-2''), 6.61 (1H, d, J = 2.1, H-6), 6.65 (1H, d, J = 7.2, CONH), 6.96 (1H, s, H-3), 7.01 (1H, d, J = 2.1, H-8), 7.56-7.69 (3H, m, H-3', H-4', H-5'), 8.14 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.95 (1H, s, OH-5).

7-O-(*N*-*t*-Butyloxycarbonyl-L-isoleucyl)-5-hydroxy-2-phenylchromen-4-one (6), yield 73%, mp 176-177°C, C₂₆H₂₉NO₇.

PMR spectrum (300 MHz, CDCl₃, δ , ppm, J/Hz): 1.04 (3H, t, J = 5.7, CH₃-5''), 1.09 (3H, d, J = 6.9, CH₃-3''), 1.44 (1H, m, CH₂-4''a), 1.45 [9H, s, (CH₃)₃C], 1.66 (1H, m, CH₂-4''b), 2.10 (1H, m, H-3''), 4.49 (1H, m, H-2''), 5.06 (1H, m, CONH), 6.59 (1H, d, J = 2.1, H-6), 6.74 (1H, s, H-3), 6.87 (1H, d, J = 2.1, H-8), 7.50-7.60 (3H, m, H-3', H-4', H-5'), 7.95 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.75 (1H, s, OH-5).

7-O-(*N*-*t*-Butyloxycarbonyl-L-phenylalanyl)-5-hydroxy-2-phenylchromen-4-one (7), yield 83%, mp 208-209°C, C₂₉H₂₇NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ, ppm, J/Hz): 1.46 [9H, s, (CH₃)₃C], 3.21-3.45 (2H, m, CH₂-3''), 4.63 (1H, q, J = 7.2, H-2''), 6.50 (1H, d, J = 2.1, H-6), 6.62 (1H, d, J = 7.2, CONH), 6.90 (1H, d, J = 2.1, H-8), 6.93 (1H, s, H-3), 7.25-7.45 (5H, m, Ph-3''), 7.58-7.69 (3H, m, H-3', H-4', H-5'), 8.12 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.93 (1H, s, OH-5).

7-O-(N-Carbobenzyloxyglycyl)-5-hydroxy-2-phenylchromen-4-one (8), yield 85%, mp 224-225°C, C₂₅H₁₉NO₇.

PMR spectrum (300 MHz, CDCl₃, δ, ppm, J/Hz): 4.27 (2H, d, J = 5.7, CH₂-2''), 5.17 (2H, s, PhCH₂CO), 5.39 (1H, m, CONH), 6.59 (1H, d, J = 2.1, H-6), 6.73 (1H, s, H-3), 6.89 (1H, d, J = 2.1, H-8), 7.37 (5H, s, PhCH₂CO), 7.51-7.62 (3H, m, H-3', H-4', H-5'), 7.89 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.74 (1H, s, OH-5).

7-O-(N-Carbobenzyloxy-L-alanyl)-5-hydroxy-2-phenylchromen-4-one (9), yield 79%, mp 209-210°C, C₂₆H₂₁NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ, ppm, J/Hz): 1.59 (3H, d, J = 7.5, CH₃-3''), 4.52 (1H, m, H-2''), 5.15 (2H, s, PhCH₂CO), 6.59 (1H, d, J = 2.1, H-6), 6.78 (1H, d, J = 7.2, CONH), 6.92 (1H, s, H-3), 6.95 (1H, d, J = 2.1, H-8), 7.28-7.44 (5H, m, PhCH₂CO), 7.55-7.69 (3H, m, H-3', H-4', H-5'), 8.11 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.90 (1H, s, OH-5).

7-O-(N-Carbobenzyloxy-L-valyl)-5-hydroxy-2-phenylchromen-4-one (10), yield 76%, mp 195-196°C, C₂₈H₂₅NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ, ppm, J/Hz): 1.13 (6H, d, J = 6.6, CH₃-4'', CH₃-3''), 2.41 (1H, m, H-3''), 4.38 (1H, t, J = 6.0, H-2''), 5.14 (2H, s, PhCH₂CO), 6.60 (1H, d, J = 2.1, H-6), 6.92 (1H, d, J = 7.5, CONH), 6.95 (1H, s, H-3), 7.01 (1H, d, J = 2.1, H-8), 7.28-7.44 (5H, m, PhCH₂CO), 7.58-7.68 (3H, m, H-3', H-4', H-5'), 8.14 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.95 (1H, s, OH-5).

7-O-(N-Carbobenzyloxy-L-leucyl)-5-hydroxy-2-phenylchromen-4-one (11), yield 83%, mp 187-188°C, C₂₉H₂₇NO₇.

PMR spectrum (300 MHz, CDCl₃, δ, ppm, J/Hz): 1.03 (6H, d, J = 5.7, CH₃-5'', CH₃-4''), 1.68-1.83 (3H, m, CH₂-3'', H-4''), 4.60 (1H, m, H-2''), 5.16 (2H, s, PhCH₂CO), 5.26 (1H, d, J = 7.2, CONH), 6.57 (1H, d, J = 2.1, H-6), 6.72 (1H, s, H-3), 6.81 (1H, d, J = 2.1, H-8), 7.30-7.44 (5H, m, PhCH₂CO), 7.54-7.65 (3H, m, H-3', H-4', H-5'), 7.91 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.73 (1H, s, OH-5).

7-O-(N-Carbobenzyloxy-L-isoleucyl)-5-hydroxy-2-phenylchromen-4-one (12), yield 77%, mp 184-185°C, C₂₉H₂₇NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ, ppm, J/Hz): 1.00 (3H, t, J = 5.7, CH₃-5''), 1.11 (3H, d, J = 6.9, CH₃-3''), 1.48 (1H, m, CH₂-4''a), 1.69 (1H, m, CH₂-4''b), 2.12 (1H, m, H-3''), 4.43 (1H, m, H-2''), 5.14 (2H, s, PhCH₂CO), 6.60 (1H, d, J = 2.1, H-6), 6.93 (1H, m, CONH), 6.95 (1H, s, H-3), 7.01 (1H, d, J = 2.1, H-8), 7.28-7.45 (5H, m, PhCH₂CO), 7.58-7.70 (3H, m, H-3', H-4', H-5'), 8.15 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.95 (1H, s, OH-5).

7-O-(N-Carbobenzyloxy-L-methionyl)-5-hydroxy-2-phenylchromen-4-one (13), yield 76%, mp 194-195°C, C₂₈H₂₅NO₇S.

PMR spectrum (300 MHz, CDCl₃, δ, ppm, J/Hz): 2.14 (3H, s, SCH₃), 2.15-2.42 (2H, m, CH₂-4''), 2.67 (2H, m, CH₂-3''), 4.76 (1H, m, H-2''), 5.16 (2H, s, PhCH₂CO), 5.54 (1H, d, J = 7.2, CONH), 6.58 (1H, d, J = 2.1, H-6), 6.75 (1H, s, H-3), 6.86 (1H, d, J = 2.1, H-8), 7.30-7.40 (5H, m, PhCH₂CO), 7.50-7.60 (3H, m, H-3', H-4', H-5'), 7.89 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.76 (1H, s, OH-5).

7-O-(N-Carbobenzyloxy-L-phenylalanyl)-5-hydroxy-2-phenylchromen-4-one (14), yield 86%, mp 228-229°C, C₃₂H₂₅NO₇.

PMR spectrum (300 MHz, CDCl₃, δ, ppm, J/Hz): 3.20-3.35 (2H, m, CH₂-3''), 4.89 (1H, q, J = 7.2, H-2''), 5.14 (2H, s, PhCH₂CO), 5.32 (1H, d, J = 7.2, CONH), 6.44 (1H, d, J = 2.1, H-6), 6.74 (1H, s, H-3), 6.78 (1H, d, J = 2.1, H-8), 7.18-7.35 (5H, m, Ph-3''), 7.50-7.60 (3H, m, H-3', H-4', H-5'), 7.91 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.75 (1H, s, OH-5).

7-O-(N-*t*-Butyloxycarbonyl-β-alanyl)-5-hydroxy-2-phenylchromen-4-one (15), yield 68%, mp 193-194°C, C₂₃H₂₃NO₇.

PMR spectrum (300 MHz, CDCl₃, δ, ppm, J/Hz): 1.47 [9H, s, (CH₃)₃C], 2.83 (2H, t, J = 7.2, CH₂-2''), 3.54 (2H, m, CH₂-3''), 5.01 (1H, m, CONH), 6.59 (1H, d, J = 2.1, H-6), 6.74 (1H, s, H-3), 6.88 (1H, d, J = 2.1, H-8), 7.52-7.61 (3H, m, H-3', H-4', H-5'), 7.92 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.74 (1H, s, OH-5).

7-O-(N-*t*-Butyloxycarbonyl-6-aminohexanoyl)-5-hydroxy-2-phenylchromen-4-one (16), yield 64%, mp 176-177°C, C₂₆H₂₉NO₇.

PMR spectrum (300 MHz, CDCl₃, δ, ppm, J/Hz): 1.42-1.78 (6H, m, CH₂-3'', CH₂-4'', CH₂-5''), 1.45 [9H, s, (CH₃)₃C], 2.60 (2H, t, J = 7.2, CH₂-2''), 3.16 (2H, m, CH₂-6''), 4.56 (1H, m, CONH), 6.57 (1H, d, J = 2.1, H-6), 6.74 (1H, s, H-3), 6.85 (1H, d, J = 2.1, H-8), 7.52-7.60 (3H, m, H-3', H-4', H-5'), 7.90 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.72 (1H, s, OH-5).

7-O-(*N*-Carbobenzyloxy- β -alanyl)-5-hydroxy-2-phenylchromen-4-one (17), yield 76%, mp 208-209°C, C₂₆H₂₁NO₇.

PMR spectrum (300 MHz, CDCl₃, δ , ppm, J/Hz): 2.86 (2H, t, J = 7.2, CH₂-2''), 3.60 (2H, m, CH₂-3''), 5.14 (2H, s, PhCH₂CO), 5.30 (1H, m, CONH), 6.57 (1H, d, J = 2.1, H-6), 6.75 (1H, s, H-3), 6.86 (1H, d, J = 2.1, H-8), 7.30-7.40 (5H, m, Ph-3''), 7.50-7.60 (3H, m, H-3', H-4', H-5'), 7.89 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.72 (1H, s, OH-5).

7-O-(*N*-Carbobenzyloxy-6-aminohexanoyl)-5-hydroxy-2-phenylchromen-4-one (18), yield 81%, mp 192-193°C, C₂₉H₂₇NO₇.

PMR spectrum (300 MHz, CD₃COCD₃, δ , ppm, J/Hz): 1.42-1.65 (4H, m, CH₂-3'', CH₂-4''), 1.72-1.80 (2H, m, CH₂-5''), 2.66 (2H, t, J = 7.2, CH₂-2''), 3.21 (2H, m, CH₂-6''), 5.06 (2H, s, PhCH₂CO), 6.38 (1H, m, CONH), 6.60 (1H, d, J = 2.1, H-6), 6.93 (1H, s, H-3), 7.02 (1H, d, J = 2.1, H-8), 7.25-7.42 (5H, m, PhCH₂CO), 7.56-7.68 (3H, m, H-3', H-4', H-5'), 8.12 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.91 (1H, s, OH-5).

7-O-(*N*-*p*-Tosyl- β -alanyl)-5-hydroxy-2-phenylchromen-4-one (19), yield 81%, mp 203-204°C, C₂₅H₂₁NO₇S.

PMR spectrum (300 MHz, CD₃COCD₃, δ , ppm, J/Hz): 2.43 (3H, s, CH₃-4'''), 2.89 (2H, t, J = 7.2, CH₂-2''), 3.35 (2H, m, CH₂-3''), 6.61 (1H, d, J = 2.1, H-6), 6.68 (1H, t, J = 7.2, SO₂NH), 6.92 (1H, s, H-3), 7.01 (1H, d, J = 2.1, H-8), 7.42 (2H, d, J = 8.1, H-3''', H-5'''), 7.55-7.65 (3H, m, H-3', H-4', H-5'), 7.82 (2H, d, J = 8.1, H-2''', H-6'''), 8.11 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.89 (1H, s, OH-5).

7-O-(*N*-*p*-Tosyl-6-aminohexanoyl)-5-hydroxy-2-phenylchromen-4-one (20), yield 76%, mp 195-196°C, C₂₈H₂₇NO₇S.

PMR spectrum (300 MHz, CDCl₃, δ , ppm, J/Hz): 1.42 (2H, m, CH₂-4''), 1.55 (2H, m, CH₂-3''), 1.72 (2H, m, CH₂-5''), 2.43 (3H, s, CH₃-4'''), 2.56 (2H, t, J = 7.2, CH₂-2''), 2.99 (2H, m, CH₂-6''), 4.55 (1H, t, J = 7.2, SO₂NH), 6.54 (1H, d, J = 2.1, H-6), 6.75 (1H, s, H-3), 6.85 (1H, d, J = 2.1, H-8), 7.32 (2H, d, J = 8.1, H-3''', H-5'''), 7.50-7.61 (3H, m, H-3', H-4', H-5'), 7.76 (2H, d, J = 8.1, H-2''', H-6'''), 7.89 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.73 (1H, s, OH-5).

Ethyl-[(5-hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetate (21). A hot solution of chrysin (25.42 g, 100 mmol) in anhydrous acetone (150 mL) was treated with freshly calcined potash (41.40 g, 0.3 mol), stirred vigorously, heated (50-56°C) for 1 h, treated dropwise with ethylbromoacetate (12.2 mL, 110 mmol), and heated for 2 h with vigorous stirring (course of reaction monitored by TLC). When the reaction was finished, the mixture was poured into H₂SO₄ solution (1 L, 1 N). The resulting precipitate was filtered and crystallized from propanol-2. Yield 86%, mp 164-165°C (lit. [36] mp 157°C), C₁₉H₁₆O₆.

PMR spectrum (300 MHz, DMSO-d₆, δ , ppm, J/Hz): 1.24 (3H, t, J = 7.2, CH₃-2'), 4.21 (2H, q, CH₂-1'), 4.96 (2H, s, OCH₂-7), 6.44 (1H, d, J = 2.1, H-6), 6.86 (1H, d, J = 2.1, H-8), 7.06 (1H, s, H-3), 7.54-7.68 (3H, m, H-3', H-4', H-5'), 8.10 (2H, dd, J = 2.1, 8.4, H-2', H-6'), 12.82 (1H, s, OH-5).

[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetic Acid (22). A solution of **21** (23.82 g, 70 mmol) in propanol-2 (150 mL) was treated with NaOH solution (150 mL, 1 N), stirred vigorously, and refluxed for 2 h (course of reaction monitored by TLC). When the reaction was finished, the mixture was treated with H₂SO₄ solution (400 mL, 1 N). The resulting precipitate was filtered and crystallized from propanol-2 (50%). Yield 91%, mp 261-262°C (lit. [37] mp 266-268°C), C₁₇H₂₁O₆.

PMR spectrum (400 MHz, DMSO-d₆, δ , ppm, J/Hz): 4.84 (2H, s, OCH₂-7), 6.39 (1H, d, J = 2.0, H-6), 6.79 (1H, d, J = 2.0, H-8), 7.01 (1H, s, H-3), 7.52-7.67 (3H, m, H-3', H-4', H-5'), 8.07 (2H, dd, J = 2.0, 8.4, H-2', H-6'), 12.15 (1H, br.s, OH-5), 12.79 (1H, s, OH-5).

***N*-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl amino Acids 23-33**. A cooled solution of acid **22** (1.25 g, 4 mmol) and *N*-hydroxysuccinimide (0.51 g, 4.4 mmol) in anhydrous DMF (10 mL) was treated with DIC (0.69 mL, 4.4 mmol) and stirred vigorously for 2 h (course of reaction monitored by TLC). The resulting *N*-hydroxysuccinimide ester was treated with a solution of the appropriate amino acid (4.4 mmol) and NaOH (0.18 g, 4.4 mmol) in water (10 mL) and stirred for 3-4 h (course of reaction monitored by TLC). After the reaction was finished, water (100 mL) was added. The pH was adjusted to 4. The precipitate was filtered and crystallized from propanol-2.

***N*-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl glycine (23)**, yield 72%, mp 264-265°C, C₁₉H₁₅NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ , ppm, J/Hz): 3.85 (2H, d, J = 6.0, CH₂-2''), 4.72 (2H, s, OCH₂-7), 6.47 (1H, d, J = 2.0, H-6), 6.85 (1H, d, J = 2.0, H-8), 7.07 (1H, s, H-3), 7.58-7.64 (3H, m, H-3', H-4', H-5'), 8.10 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.53 (1H, d, J = 5.6, CONH), 12.35 (1H, br.s, COOH), 12.82 (1H, s, OH-5).

***N*-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-L-alanine (24)**, yield 81%, mp 249-250°C, C₂₀H₁₇NO₇.

PMR spectrum (300 MHz, DMSO-d₆, δ, ppm, J/Hz): 1.33 (3H, d, J = 7.2, CH₃-2''), 4.29 (1H, m, H-2''), 4.80 (2H, q, J = 8.0, OCH₂-7), 6.43 (1H, d, J = 2.0, H-6), 6.79 (1H, d, J = 2.0, H-8), 7.06 (1H, s, H-3), 7.58-7.65 (3H, m, H-3', H-4', H-5'), 8.09 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.37 (1H, d, J = 7.2, CONH), 12.40 (1H, br.s, COOH), 12.79 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-L-valine (25), yield 77%, mp 254-255°C, C₂₂H₂₁NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 0.92 (6H, d, J = 7.2, CH₃-4'', CH₃-3''), 2.13 (1H, m, H-3''), 4.24 (1H, m, H-2''), 4.80 (2H, q, J = 8.0, OCH₂-7), 6.43 (1H, d, J = 2.0, H-6), 6.79 (1H, d, J = 2.0, H-8), 7.06 (1H, s, H-3), 7.58-7.65 (3H, m, H-3', H-4', H-5'), 8.09 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.33 (1H, d, J = 8.4, CONH), 12.48 (1H, br.s, COOH), 12.79 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-L-methionine (26), yield 74%, mp 232-233°C, C₂₂H₂₁NO₇S.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 1.95-2.08 (2H, m, CH₂-4''), 2.02 (3H, s, SCH₃), 2.45 (2H, m, CH₂-3''), 4.42 (1H, m, H-2''), 4.74 (2H, q, J = 8.0, OCH₂-7), 6.45 (1H, d, J = 2.0, H-6), 6.81 (1H, d, J = 2.0, H-8), 7.07 (1H, s, H-3), 7.57-7.64 (3H, m, H-3', H-4', H-5'), 8.09 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.42 (1H, d, J = 7.6, CONH), 12.64 (1H, br.s, COOH), 12.81 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-L-phenylalanine (27), yield 88%, mp 268-269°C, C₂₆H₂₁NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 2.99 (1H, dd, J = 12.0, 16.4, CH₂-3''a), 3.10 (1H, dd, J = 2.8, 16.4, CH₂-3''b), 4.52 (1H, m, H-2''), 4.65 (2H, q, J = 8.8, OCH₂-7), 6.41 (1H, d, J = 2.0, H-6), 6.72 (1H, d, J = 2.0, H-8), 7.08 (1H, s, H-3), 7.13-7.21 (5H, m, Ph-3''), 7.57-7.64 (3H, m, H-3', H-4', H-5'), 8.09 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.44 (1H, d, J = 8.0, CONH), 12.60 (1H, br.s, COOH), 12.82 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-L-phenylglycine (28), yield 78%, mp 276-277°C, C₂₅H₁₉NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 4.81 (2H, q, J = 8.8, OCH₂-7), 5.43 (1H, d, J = 7.2, H-2''), 6.44 (1H, d, J = 2.0, H-6), 6.79 (1H, d, J = 2.0, H-8), 7.06 (1H, s, H-3), 7.25-7.45 (5H, m, Ph-2''), 7.56-7.64 (3H, m, H-3', H-4', H-5'), 8.09 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.93 (1H, d, J = 7.6, CONH), 12.65 (1H, br.s, COOH), 12.81 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-β-alanine (29), yield 83%, mp 252-253°C, C₂₀H₁₇NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 2.44 (2H, t, J = 6.8, CH₂-2''), 3.36 (2H, m, CH₂-3''), 4.64 (2H, s, OCH₂-7), 6.44 (1H, d, J = 2.0, H-6), 6.82 (1H, d, J = 2.0, H-8), 7.06 (1H, s, H-3), 7.58-7.64 (3H, m, H-3', H-4', H-5'), 8.11 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.23 (1H, d, J = 5.2, CONH), 12.35 (1H, br.s, COOH), 12.82 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-4-aminobutanoic acid (30), yield 76%, mp 248-249°C, C₂₁H₁₉NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 1.69 (2H, m, CH₂-3''), 2.24 (2H, t, J = 6.8, CH₂-2''), 3.17 (2H, m, CH₂-4''), 4.64 (2H, s, OCH₂-7), 6.45 (1H, d, J = 2.0, H-6), 6.82 (1H, d, J = 2.0, H-8), 7.05 (1H, s, H-3), 7.57-7.64 (3H, m, H-3', H-4', H-5'), 8.09 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.22 (1H, d, J = 5.2, CONH), 12.10 (1H, br.s, COOH), 12.81 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-6-aminohexanoic acid (31), yield 81%, mp 225-226°C, C₂₃H₂₃NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 1.22 (2H, m, CH₂-4''), 1.44 (4H, m, CH₂-3'', CH₂-5''), 2.16 (2H, t, J = 7.2, CH₂-2''), 3.14 (2H, m, CH₂-6''), 4.63 (2H, s, OCH₂-7), 6.45 (1H, d, J = 2.0, H-6), 6.83 (1H, d, J = 2.0, H-8), 7.07 (1H, s, H-3), 7.57-7.64 (3H, m, H-3', H-4', H-5'), 8.10 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.18 (1H, d, J = 5.2, CONH), 11.90 (1H, br.s, COOH), 12.82 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetyl-trans-4-aminomethylcyclohexane carboxylic acid (32), yield 86%, mp 264-265°C, C₂₅H₂₅NO₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 0.88 and 1.18 (4H, two m, CH₂-3'', CH₂-5''), 1.25 (1H, m, H-4''), 1.73 and 1.87 (4H, two m, CH₂-3'', CH₂-5''), 2.10 (1H, m, H-1''), 3.00 (2H, t, J = 7.2, CH₂-1''), 4.66 (2H, s, OCH₂-7), 6.45 (1H, d, J = 2.0, H-6), 6.81 (1H, d, J = 2.0, H-8), 7.06 (1H, s, H-3), 7.57-7.64 (3H, m, H-3', H-4', H-5'), 8.10 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.15 (1H, d, J = 5.6, CONH), 12.05 (1H, br.s, COOH), 12.81 (1H, s, OH-5).

N-[(5-Hydroxy-4-oxo-2-phenylchromen-7-yl)oxy]acetylglucylglycine (33), yield 69%, mp 235-236°C, C₂₁H₁₈N₂O₇.

PMR spectrum (400 MHz, DMSO-d₆, δ, ppm, J/Hz): 3.80 and 3.85 (4H, two d, J = 6.0, CH₂-2'', CH₂-2'''), 4.72 (2H, s, OCH₂-7), 6.48 (1H, d, J = 2.0, H-6), 6.89 (1H, d, J = 2.0, H-8), 7.07 (1H, s, H-3), 7.57-7.64 (3H, m, H-3', H-4', H-5'), 8.12 (2H, dd, J = 2.0, 8.0, H-2', H-6'), 8.18, 8.20 (two t, J = 5.6, two CONH), 12.45 (1H, br.s, COOH), 12.82 (1H, s, OH-5).

ACKNOWLEDGMENT

We thank OAO Eksimed (Kiev, Ukraine) for help with performing the work.

REFERENCES

1. J. B. Harborne and C. A. Williamson, *Phytochemistry*, **55**, 481 (2000).
2. B. H. Havsteen, *Pharmacol. Ther.*, **96**, 67 (2002).
3. C. A. Williams, J. B. Harborne, M. Netman, J. Greenham, and J. Eagles, *Phytochemistry*, **46**, 1349 (1997).
4. V. M. Malikov and M. P. Yuldashev, *Khim. Prir. Soedin.*, 299 (2002).
5. M. Cardenas, M. Marder, V. C. Blank, and L. P. Roguin, *Bioorg. Med. Chem.*, **14**, 2966 (2006).
6. Y.-P. Lin, F.-L. Hsu, C.-S. Chen, J.-W. Chern, and M.-H. Lee, *Phytochemistry*, **68**, 1189 (2007).
7. G. Beyer and M. F. Melzig, *Planta Med.*, **69**, 1125 (2003).
8. J. Vaya, S. Mahmood, A. Goldblum, M. Aviram, N. Volkova, A. Shaalan, R. Musa, and S. Tamir, *Phytochemistry*, **62**, 89 (2003).
9. K. Y. Park, S.-H. Lee, B.-K. Min, K.-S. Lee, J.-S. Choi, S. R. Chung, K. R. Min, and Y. Kim, *Planta Med.*, **65**, 457 (1999).
10. T. Nagaoka, A. H. Banskota, Y. Tezuka, K. Midorikawa, K. Matsushige, and S. Kadota, *Biol. Pharm. Bull.*, **26**, 487 (2003).
11. J. Duarte, R. Jimenez, I. C. Villar, F. Perez-Vizcaino, J. Jimenez, and J. Tamargo, *Planta Med.*, **67**, 567 (2001).
12. I. C. Villar, R. Vera, M. Galisteo, F. O'Valle, M. Romero, A. Zarzuelo, and J. Duarte, *Planta Med.*, **71**, 829 (2005).
13. H. Kuwabara, K. Mouri, H. Otsuka, R. Kasai, and K. Yamasaki, *J. Nat. Prod.*, **66**, 1273 (2003).
14. N. Orsolich, I. Kosalec, and I. Basic, *Biol. Pharm. Bull.*, **28**, 694 (2005).
15. K. S. Babu, T. H. Babu, P. V. Srinivas, K. H. Kishore, U. S. N. Murthy, and J. M. Rao, *Bioorg. Med. Chem. Lett.*, **16**, 221 (2006).
16. E. Melliou and I. Chinou, *Planta Med.*, **70**, 515 (2004).
17. M. del Rayo Camacho, J. D. Phillipson, S. L. Croft, V. Yardley, and P. N. Solis, *Planta Med.*, **70**, 70 (2004).
18. S. S. Kang, J. Y. Lee, Y. K. Choi, G. S. Kim, and B. H. Han, *Bioorg. Med. Chem. Lett.*, **14**, 2261 (2004).
19. I. C. Villar, R. Jimenez, M. Galisteo, M. F. Garcia-Saura, A. Zarzuelo, and J. Duarte, *Planta Med.*, **68**, 847 (2002).
20. H. Mastuda, T. Morikawa, K. Ueda, H. Managi, and M. Yoshikawa, *Bioorg. Med. Chem.*, **10**, 3123 (2002).
21. J.-S. Shin, K.-S. Kim, M.-B. Kim, J.-H. Jeong, and B.-K. Kim, *Bioorg. Med. Chem. Lett.*, **9**, 869 (1999).
22. X. Zheng, W.-D. Meng, Y.-Y. Xu, J.-G. Cao, and F.-L. Qinga, *Bioorg. Med. Chem. Lett.*, **13**, 881 (2003).
23. T. Zhang, X. Chen, L. Qu, J. Wu, R. Cuia, and Y. Zhao, *Bioorg. Med. Chem.*, **12**, 6097 (2004).
24. C.-L. Wang, H.-Q. Li, W.-D. Menga, and F.-L. Qinga, *Bioorg. Med. Chem. Lett.*, **15**, 4456 (2005).
25. G. Comte, J.-B. Daskiewicz, C. Bayer, G. Conseil, A. Viornery-Vanier, C. Dumontet, A. Di Pietro, and D. Barron, *J. Med. Chem.*, **44**, 763 (2001).
26. T. T. Dao, Y. S. Chi, J. Kim, H. P. Kim, S. Kim, and H. Park, *Bioorg. Med. Chem. Lett.*, **14**, 1165 (2004).
27. H. Park, T. T. Dao, and H. P. Kim, *Eur. J. Med. Chem.*, **40**, 943 (2005).
28. A. A. Gershkovich and V. K. Kibirev, *Chemical Synthesis of Peptides* [in Russian], Naukova Dumka, Kiev (1992), p. 71.
29. M. M. Garazd, V. V. Arkhipov, N. K. Proskurka, and V. P. Khilya, *Khim. Geterotsikl. Soedin.*, 744 (1999).
30. M. M. Garazd, Ya. L. Garazd, and V. P. Khilya, *Khim. Prir. Soedin.*, 29 (2001).

31. M. M. Garazd, Ya. L. Garazd, A. S. Ogorodniichuk, V. V. Shilin, A. V. Turov, and V. P. Khilya, *Khim. Prir. Soedin.*, 466 (1998).
32. J. Kim, Y. Lee, H. Kim, S.-Y. Kang, K.-S. Park, J.-H. Cho, Y.-Y. Lee, B.-S. Kim, Y. Lim, and Y. Chong, *Bull. Kor. Chem. Soc.*, **26**, 2065 (2005).
33. G. W. Anderson, J. Zimmerman, and F. M. Callahan, *J. Am. Chem. Soc.*, **85**, 3039 (1963).
34. T. V. Shokol, A. S. Ogorodniichuk, V. V. Shilin, V. B. Milevskaya, and V. P. Khilya, *Khim. Geterotsikl. Soedin.*, 482 (1998).
35. S. Saxena, J. K. Makrandi, and S. K. Grover, *Synthesis*, 697 (1985).
36. M. T. Briggs, G. L. S. Duncan, and C. W. Thornber, *J. Chem. Res. Miniprint*, **9**, 2461 (1982).
37. Blaise, FRM 1406; *Chem. Abstr.*, **58**, 7911b (1963).